Unum Therapeutics acquires kinase inhibitors developer Kiq
Unum Therapeutics, a US biopharma company, has acquired Kiq, a biotech company focused on the discovery and development of precision kinase inhibitors, in an all-stock deal. Focused on developing therapies for solid tumors, Unum Therapeutics, through the deal gains access to a clinical-stage compound called PLX9486, which is a selective KIT D816V inhibitor. More...
Gilead Sciences announces Veklury EU approval for COVID-19 treatment
Veklury EU approval : Gilead Sciences said that Veklury (remdesivir) has been given conditional marketing authorization from European Commission as a treatment for SARS-CoV-2 infection, the virus behind COVID-19. According More...
ViiV Healthcare bags Rukobia FDA approval for HIV patients with limited treatment options
Rukobia FDA approval : ViiV Healthcare said that the US Food and Drug Administration (FDA) has approved Rukobia (fostemsavir), 600 mg extended-release tablets as a new treatment of HIV patients having limited treatment More...
Medivir gets orphan medicinal product designation for MIV-818 for HCC in EU
Swedish biotech company Medivir has secured orphan medicinal product designation from the European Commission for MIV-818 for the treatment of hepatocellular carcinoma (HCC). The orphan medicinal product designation More...
BrainStorm Cell Therapeutics doses patients in NurOwn phase 3 trial in ALS
NurOwn phase 3 trial : BrainStorm Cell Therapeutics, a US biotech company engaged in developing adult stem cell therapies for neurodegenerative diseases, has completed the dosing of all the participants in a phase More...
China’s CF PharmTech raises $50m in Series F round for inhalation products
CF PharmTech, a Chinese pharma company, has raised $50 million in a Series F financing round to accelerate the commercialization of its inhalation products. The investors who took part in the Series F funding round More...
India-based Piramal Pharma secures $490m investment from Carlyle Group
The Carlyle Group has signed a deal worth around $490 million with Piramal Enterprises, to acquire a stake of 20% from the Indian conglomerate’s pharma business – Piramal Pharma. The US-based private More...
Celltex Therapeutics gets FDA nod for Covid-19 stem cell clinical trial
Covid-19 stem cell clinical trial : Celltex Therapeutics has been given the clearance by the US Food and Drug Administration (FDA) to move ahead with a phase 2 clinical trial for investigating the efficacy of autologous More...
Masimo gets FDA clearance for Centroid patient monitoring sensor
Masimo, a US medical device company, has received clearance from the US Food and Drug Administration (FDA) for Centroid, the company’s wearable, wireless patient orientation, activity, and respiration rate More...
EC approves Reblozyl for transfusion-dependent anemia in adults
Bristol Myers Squibb and Acceleron Pharma have secured approval from the European Commission (EC) for their jointly developed erythroid maturation agent Reblozyl (luspatercept) for the treatment of transfusion-dependent More...